Logo image of ALGEC.PA

GECI INTERNATIONAL (ALGEC.PA) Stock Fundamental Analysis

EPA:ALGEC - Euronext Paris - Matif - FR001400M1R1 - Common Stock - Currency: EUR

3.5  -0.02 (-0.57%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ALGEC. ALGEC was compared to 34 industry peers in the Professional Services industry. Both the profitability and financial health of ALGEC have multiple concerns. ALGEC is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year ALGEC was profitable.
In the past year ALGEC had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: ALGEC reported negative net income in multiple years.
In the past 5 years ALGEC reported 4 times negative operating cash flow.
ALGEC.PA Yearly Net Income VS EBIT VS OCF VS FCFALGEC.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M -6M

1.2 Ratios

ALGEC has a better Return On Assets (6.42%) than 70.59% of its industry peers.
ALGEC has a better Return On Equity (19.84%) than 73.53% of its industry peers.
Industry RankSector Rank
ROA 6.42%
ROE 19.84%
ROIC N/A
ROA(3y)-2.06%
ROA(5y)-5.64%
ROE(3y)-30.89%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALGEC.PA Yearly ROA, ROE, ROICALGEC.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

ALGEC has a Profit Margin of 4.65%. This is in the better half of the industry: ALGEC outperforms 64.71% of its industry peers.
In the last couple of years the Profit Margin of ALGEC has grown nicely.
ALGEC has a Gross Margin of 19.83%. This is in the lower half of the industry: ALGEC underperforms 64.71% of its industry peers.
ALGEC's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 4.65%
GM 19.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y1.57%
PM growth 5YN/A
GM growth 3Y-5.81%
GM growth 5Y-7.26%
ALGEC.PA Yearly Profit, Operating, Gross MarginsALGEC.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

3

2. Health

2.1 Basic Checks

ALGEC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALGEC has been increased compared to 1 year ago.
ALGEC has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, ALGEC has an improved debt to assets ratio.
ALGEC.PA Yearly Shares OutstandingALGEC.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
ALGEC.PA Yearly Total Debt VS Total AssetsALGEC.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

ALGEC has an Altman-Z score of 0.37. This is a bad value and indicates that ALGEC is not financially healthy and even has some risk of bankruptcy.
ALGEC's Altman-Z score of 0.37 is on the low side compared to the rest of the industry. ALGEC is outperformed by 88.24% of its industry peers.
ALGEC has a debt to FCF ratio of 5.92. This is a neutral value as ALGEC would need 5.92 years to pay back of all of its debts.
ALGEC has a Debt to FCF ratio of 5.92. This is comparable to the rest of the industry: ALGEC outperforms 41.18% of its industry peers.
A Debt/Equity ratio of 0.14 indicates that ALGEC is not too dependend on debt financing.
With an excellent Debt to Equity ratio value of 0.14, ALGEC belongs to the best of the industry, outperforming 88.24% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF 5.92
Altman-Z 0.37
ROIC/WACCN/A
WACC6.03%
ALGEC.PA Yearly LT Debt VS Equity VS FCFALGEC.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

ALGEC has a Current Ratio of 0.80. This is a bad value and indicates that ALGEC is not financially healthy enough and could expect problems in meeting its short term obligations.
ALGEC has a worse Current ratio (0.80) than 67.65% of its industry peers.
A Quick Ratio of 0.80 indicates that ALGEC may have some problems paying its short term obligations.
ALGEC's Quick ratio of 0.80 is on the low side compared to the rest of the industry. ALGEC is outperformed by 67.65% of its industry peers.
Industry RankSector Rank
Current Ratio 0.8
Quick Ratio 0.8
ALGEC.PA Yearly Current Assets VS Current LiabilitesALGEC.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

2

3. Growth

3.1 Past

ALGEC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 114.72%, which is quite impressive.
ALGEC shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.43%.
ALGEC shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -5.29% yearly.
EPS 1Y (TTM)114.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.79%
Revenue 1Y (TTM)10.43%
Revenue growth 3Y10.84%
Revenue growth 5Y-5.29%
Sales Q2Q%-17.02%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALGEC.PA Yearly Revenue VS EstimatesALGEC.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 4.86, the valuation of ALGEC can be described as very cheap.
Based on the Price/Earnings ratio, ALGEC is valued cheaper than 100.00% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.32, ALGEC is valued rather cheaply.
Industry RankSector Rank
PE 4.86
Fwd PE N/A
ALGEC.PA Price Earnings VS Forward Price EarningsALGEC.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, ALGEC is valued cheaply inside the industry as 85.29% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 8.58
EV/EBITDA N/A
ALGEC.PA Per share dataALGEC.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALGEC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GECI INTERNATIONAL

EPA:ALGEC (6/17/2025, 7:00:00 PM)

3.5

-0.02 (-0.57%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCommercial & Professional Services
GICS IndustryProfessional Services
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners1.57%
Ins Owner ChangeN/A
Market Cap3.57M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 4.86
Fwd PE N/A
P/S 0.16
P/FCF 8.58
P/OCF 8.13
P/B 0.67
P/tB N/A
EV/EBITDA N/A
EPS(TTM)0.72
EY20.57%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.41
FCFY11.65%
OCF(TTM)0.43
OCFY12.3%
SpS22.28
BVpS5.22
TBVpS-1.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 6.42%
ROE 19.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 4.65%
GM 19.83%
FCFM 1.83%
ROA(3y)-2.06%
ROA(5y)-5.64%
ROE(3y)-30.89%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y1.57%
PM growth 5YN/A
GM growth 3Y-5.81%
GM growth 5Y-7.26%
F-Score6
Asset Turnover1.38
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF 5.92
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 39.39%
Current Ratio 0.8
Quick Ratio 0.8
Altman-Z 0.37
F-Score6
WACC6.03%
ROIC/WACCN/A
Cap/Depr(3y)74.78%
Cap/Depr(5y)48.89%
Cap/Sales(3y)0.72%
Cap/Sales(5y)0.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)114.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.79%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)10.43%
Revenue growth 3Y10.84%
Revenue growth 5Y-5.29%
Sales Q2Q%-17.02%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3130.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y135.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y138.17%
OCF growth 3YN/A
OCF growth 5YN/A